Abiraterone prodrugs
AssigneePropella Therapeutics, Inc.
InventorsMatthew J. SHARP, William R. Moore, JR.
Life of this patent
Estimating the term…
Abstract
Sustained-release abiraterone prodrug formulations, methods, and kits for parenteral administration to a subject having a sex hormone-dependent benign or malignant disorder such as prostate cancer, a syndrome due to androgen excess, and/or a syndrome due to glucocorticoid excess such as hypercortisolemia.
Claims54
A compound having the following formula,
A pharmaceutical composition comprising:
- 1) abiraterone decanoate having the following formula,
- 2) a pharmaceutically acceptable oil, and
- 3) benzyl alcohol and/or benzyl benzoate,
- wherein the abiraterone decanoate is in its basic form.
A unit dosage form comprising:
- 1) about 50 mg to about 2,000 mg abiraterone decanoate having the following formula,
- 2) a pharmaceutically acceptable oil, and
- 3) a pharmaceutically acceptable solvent,
- wherein the abiraterone decanoate is in its basic form, which is present at a concentration of about 25 mg/ml to about 500 mg/ml.
A pharmaceutical composition comprising a compound of Formula II, or a pharmaceutically acceptable salt thereof, wherein the pharmaceutical composition is formulated for intramuscular injection, intradermal injection, or subcutaneous injection, and the compound of Formula II or pharmaceutically acceptable salt thereof is present in the pharmaceutical composition at a concentration of about 25 mg/ml to about 500 mg/ml,
- wherein R2 is R20, OR20, or NHR20,
- wherein R20 is selected from:
- a C1-30 alkyl;
- a C2-30 alkenyl;
- a C2-30 alkynyl;
- an alkyl substituted with a cycloalkyl, which has a total number of carbons between 4 and 30;
- an alkyl substituted with a phenyl, which has a total number of carbons between 7 and 30;
- and a cycloalkyl optionally substituted with one or more alkyl, which has a total number of carbons between 3 and 30.
Dependencies are inferred from the claim text.